Summary
Intuitive Surgical Inc. (ISRG) reported a significant year-over-year decrease in revenue for the first quarter of 2014, driven primarily by a sharp decline in system sales. This was partially offset by a modest increase in recurring revenue from services, instruments, and accessories. The company's net income also saw a substantial decrease, largely impacted by a significant pre-tax charge of $67.4 million related to product liability claims. Despite the revenue dip, the company continues to invest in research and development and has launched its new da Vinci Xi Surgical System, which received FDA clearance in April 2014. Financially, ISRG maintained a strong cash position with $3.0 billion in cash, cash equivalents, and investments as of March 31, 2014. However, the significant litigation charge and the decline in system sales warrant investor attention. The company is also navigating evolving trends in surgical procedures, including pressure on benign gynecologic procedures and a decline in U.S. prostatectomy procedures, alongside a strategic pivot towards less complex procedures in its U.S. market.
Financial Highlights
47 data points| Revenue | $464.70M |
| Cost of Revenue | $149.30M |
| Gross Profit | $315.40M |
| R&D Expenses | $43.00M |
| SG&A Expenses | $215.80M |
| Operating Expenses | $258.80M |
| Operating Income | $56.60M |
| Net Income | $44.30M |
| EPS (Basic) | $0.13 |
| EPS (Diluted) | $0.13 |
| Shares Outstanding (Basic) | 344.70M |
| Shares Outstanding (Diluted) | 351.90M |
Key Highlights
- 1Total revenue decreased by 24% to $464.7 million in Q1 2014 compared to Q1 2013, primarily due to a 59% decrease in system revenue.
- 2Recurring revenue (services, instruments, and accessories) increased slightly by 1% to $358.7 million, now representing 77% of total revenue, up from 58% in the prior year's quarter.
- 3Net income plummeted to $44.3 million from $188.9 million year-over-year, significantly impacted by a $67.4 million pre-tax charge for product liability claims.
- 4The company shipped 87 da Vinci Surgical Systems in Q1 2014, a substantial decrease from 164 units shipped in Q1 2013.
- 5Installed base of da Vinci Surgical Systems grew to 3,039 as of March 31, 2014.
- 6The company launched its new da Vinci Xi Surgical System in April 2014, receiving FDA clearance.
- 7Cash, cash equivalents, and investments stood strong at $3.0 billion as of March 31, 2014.